RFA Plus Carrizumab vs Carrizumab Alone for HCC

This study is comparing two treatments for hepatocellular carcinoma (the most common form of liver cancer): an immunotherapy drug called carrizumab alone versus carrizumab combined with radiofrequency ablation (RFA), a procedure that uses heat to destroy tumors. The goal is to see if combining both approaches works better than the drug alone. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with liver cancer (HCC) confirmed by biopsy or pathology - Your cancer is at intermediate or advanced stage (BCLC B or C) - Surgery or liver transplant is not an option for you - You have not yet received any systemic (whole-body) therapy for this cancer - Your liver function is still reasonably preserved (Child-Pugh A or B) - If you have hepatitis B or C, it must be controlled with antiviral treatment **You may NOT be eligible if...** - You have a different type of liver cancer (such as bile duct cancer or mixed type) - You have another active cancer Talk to your doctor to see if this trial is right for you.